Dr. Diana Escolar M.D. serves as Chief Medical Officer of the Company. Prior to serving as our Chief Medical Officer, Dr. Escolar served as our Senior Vice President of Clinical Science from January 2018 to December 2019. Prior to joining us, from June 2011 to September 2017, Dr. Escolar was the Chief Medical Officer of Akashi Therapeutics, Inc. (previously DART Therapeutics, Inc.). Prior to serving at Akashi Therapeutics, from June 2009 to June 2011, Dr. Escolar was a Principal Medical Consultant for Acceleron Pharma. From 2011 to 2012, Dr. Escolar served as Senior Medical Consultant and Advisory Board Member for Shire Plc. From 2003 to 2005, Dr. Escolar served as a Principal Medical Consultant for the Genzyme Corporation. Between 2004 and 2011, Dr. Escolar also held multiple positions on advisory boards or as a medical consultant for national and international companies, as well as government agencies, such as Wyeth, Summit Therapeutics, AVI Biopharma, PTC Therapeutics, Aileron Therapeutics, the Center for Disease Control, and as a scientific reviewer for the National Institute of Health. From 2000 to 2007, Dr. Escolar also served as the co-founder and director of the Cooperative International Neuromuscular Research Group. From 2010 to 2017, Dr. Escolar served as an Associate Professor of Neurology at Johns Hopkins University as well as Faculty at the Kennedy Krieger Institute from. Dr. Escolar received her M.D. from the University of Buenos Aires, School of Medicine in Argentina, and she completed her post-graduate training with Boston University- and Harvard Medical School-affiliated programs.
As the Chief Medical Officer of Miragen Therapeutics Inc, the total compensation of Diana Escolar at Miragen Therapeutics Inc is $543,788. There are no executives at Miragen Therapeutics Inc getting paid more.
Diana Escolar is 58, he's been the Chief Medical Officer of Miragen Therapeutics Inc since 2019. There are 4 older and 4 younger executives at Miragen Therapeutics Inc. The oldest executive at Miragen Therapeutics Inc is Arlene Morris, 68, who is the Independent Director.
Diana's mailing address filed with the SEC is C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG. 300, SUITE 201, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Miragen Therapeutics Inc have traded over $636,110 worth of Miragen Therapeutics Inc stock and bought 1,041,411 units worth $5,368,137 . The most active insiders traders include Bennett S Lebow, Bruce Booth und Paul D Rubin. On average, Miragen Therapeutics Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,345,685. The most recent stock trade was executed by Global Master Fund Lp Logos on 9 November 2020, trading 476,667 units of MGEN stock currently worth $2,268,935.
Miragen Therapeutics Inc executives and other stock owners filed with the SEC include: